Clinical Trial Update: Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) [Phase 2]

View source ↗

Summary

A Phase 2 MATCH subprotocol trial testing nivolumab with relatlimab (BMS-986016) for LAG-3 positive tumors with mismatch repair deficiency has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Malignant Neoplasm

Drugs mentioned

• OPDIVO (nivolumab)
• Relatlimab (relatlimab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: WITHDRAWN